Plain-English translation of NCT07021794 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to see if it can help people who are suffering from long-term COVID symptoms—the health problems that linger weeks or months after the initial infection. Researchers believe that ongoing inflammation in the body may be driving these prolonged symptoms, and this treatment is designed to target that inflammation. You would receive one injection and be followed for six months to see if your symptoms improve.
Many people recover quickly from COVID-19, but others develop symptoms that persist for months—such as exhaustion, shortness of breath, muscle pain, and brain fog. Early research suggests that this medication might help by reducing the body's inflammatory response, but it hasn't been tested yet in people with long COVID. This trial will tell us whether this treatment actually works.
You likely qualify if…
You likely don't qualify if…
You would receive one intramuscular injection (either the active medication or a placebo saline injection that looks identical) and then attend follow-up visits over six months to track any changes in your symptoms. The researchers will monitor how you're doing through questionnaires and clinical assessments. After six months, if you're still experiencing long COVID symptoms, you would have the option to continue into an additional phase where everyone receives the active treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
Nancy Klimas
Collaborators
Florida Department of Health
Enrollment target
~100 participants
Started
July 2025
Primary completion
September 2027
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nancy Klimas, MD
Nova Southeastern University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.